

Pan-Canadian Pharmaceutical Alliance: Negotiations being considered by each Province/Territory

As of September 30, 2019

The pCPA has recommended that negotiations for the following 13 brand name drug products be considered by each Province/Territory individually:

| Drug Product Brand Name (Generic Name) | Indication/Use |
|---|---|
| Actemra (tocilizumab) | Used to treat polyarticular juvenile idiopathic arthritis (pJIA) |
| Botox (onabotulinumtoxinA) | Used to treat chronic migraine |
| Botox (onabotulinumtoxinA) | Used to treat overactive bladder |
| Fycompa (perampanel) | Used to treat seizures |
| Genotropin (somatropin) | Used to treat growth hormone deficiency and Turner's syndrome |
| Humalog 200 units/ml (insulin lispro) | Used to treat Type 1 and Type 2 diabetes |
| Humira (adalimumab) | Used to treat polyarticular juvenile idiopathic arthritis |
| Jentadueto (linagliptin/metformin) | Used to treat Type 2 diabetes |
| Komboglyze (saxagliptin/metformin) | Used to treat Type 2 diabetes |
| Latuda (lurasidone) | Used to treat schizophrenia |
| Lodalis powder for oral solution (colesevelam) | Used to treat hypercholesterolemia (line extension) |
| Lucentis (ranibizumab) | Used to treat choroidal neovascularization secondary to pathologic myopia |
| Trisenox (arsenic trioxide) | Used to treat acute promyelocytic leukemia |

* No new drug products since last update of August 31, 2019.

Factors considered by provinces and territories in pursuing individual drug negotiations include Canadian Drug Expert Committee (CDEC) or pan-Canadian Oncology Drug Review Expert Review Committee (pERC) recommendations, listing status of alternatives and the overall value of joint negotiations for the particular product.